Tafamidis for Transthyretin Amyloid Cardiomyopathy

Christopher Manion^{1

2}, Umesh C Sharma¹

Affiliations

Comment

Christopher Manion et al. N Engl J Med. 2019.

. 2019 Jan 10;380(2):196.

doi: 10.1056/NEJMc1814074.

Christopher Manion^{1

2}, Umesh C Sharma¹

No abstract available

Comment in

Tafamidis for Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Sultan MB, Rapezzi C. Maurer MS, et al. N Engl J Med. 2019 Jan 10;380(2):196-197. doi: 10.1056/NEJMc1814074. N Engl J Med. 2019. PMID: 30625051 No abstract available.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Maurer MS, et al. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27. N Engl J Med. 2018. PMID: 30145929 Clinical Trial.